Veeva Systems (NYSE: VEEV) reported strong fiscal first-quarter results on Thursday, surpassing analyst expectations and raising its full-year guidance. However, the life sciences software company's shares slipped 2.5% in premarket trading to $178.72, as investors remained cautious about the potential impact of artificial intelligence on revenue, slower services growth, and customer migration challenges amid stiff competition from Salesforce and IQVIA.
Q1 Results Beat Consensus
For the quarter ended April 30, Veeva posted total revenue of $882.9 million, a 16% increase year-over-year and above the consensus estimate of $857.75 million from Investing.com. Subscription revenue rose 15% to $730.2 million. Adjusted earnings per share came in at $2.24, also exceeding the $2.14 estimate. Non-GAAP operating income reached $395.4 million, up from $349.9 million in the same period last year, excluding items such as stock-based compensation.
Guidance Raised for Fiscal 2027
CFO Brian Van Wagener noted that the quarter exceeded all guidance metrics, with broad-based growth and profitability. Veeva now expects second-quarter revenue between $902 million and $905 million. For the full fiscal year 2027, the company raised its revenue forecast to a range of $3.635 billion to $3.645 billion, with adjusted EPS of approximately $9.05.
AI Strategy and Product Launches
CEO Peter Gassner emphasized the company's AI progress, stating that current developments "set the foundation" for future growth. Veeva is positioning itself as more than a traditional software vendor, aiming to become a provider of applications and AI agents tailored to the life sciences sector. The company reported that over 50 brands now use Ostro, a conversational AI platform acquired in March. Vault AI is scheduled for broad rollout across all Vault apps in August, and early adopters will gain access to Veeva Falcon before year-end. Falcon will initially handle trial master file document intake, quality checks, regulatory correspondence with health authorities, and safety case triage.
Customer Wins and Competitive Landscape
Veeva added 27 new Vault CRM customers in the quarter, bringing total users above 150. CRM software enables clients to manage sales, marketing, and medical communications with healthcare professionals. However, the company's latest annual filing highlights Salesforce as the primary competitor in CRM, while IQVIA also poses a threat through its CRM licensing deal with Salesforce. Veeva acknowledged risks related to its transition to Vault CRM, noting that some customers have chosen or may choose alternative vendors.
Analyst Reaction and Market Sentiment
Raymond James lowered its price target on Veeva stock to $225 from $275 but maintained an Outperform rating. The firm described the beat-and-raise headline as strong but noted that some investors might overlook the guidance hike due to concerns about services and deal activity. It also warned that volatility in the software sector could weigh on shares.
Downside Risks Remain
The market's cautious response underscores lingering risks. If AI revenue fails to materialize quickly, or if Vault CRM conversions lag as Salesforce intensifies its push into life sciences, Veeva's AI narrative could remain more about promise than profit. The company's own filings cite risks including intensified competition, pricing pressure, and potential customer losses that could erode revenue and margins.
Thursday's regular trading session will be closely watched. While Veeva delivered a beat and raised guidance, the premarket decline suggests that Wall Street wants more concrete evidence that the company's AI and CRM initiatives will translate into sustainable recurring revenue.
